Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis...
June 18 2018 - 7:30AM
Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc.
(NASDAQ:FBIO) Company developing treatments for rare and
life-threatening diseases, today announced that Columbia University
(“Columbia”) will present a complete analysis of cardiac data from
the Phase 1b trial of CAEL-101 (mAb 11-1F4) for the treatment of
relapsed or refractory amyloid light chain (“AL”) amyloidosis in a
poster session at the American Society of Echocardiography (ASE)
29th Annual Scientific Sessions, to be held June 22-26, 2018, in
Nashville, Tenn.
Investigators concluded that the Phase 1b trial
of CAEL-101 in AL amyloidosis is the first trial to show a
significant improvement in global longitudinal strain (“GLS”) after
exposure to an anti-fibril specific mAb in subjects with AL
amyloidosis experiencing cardiac involvement. GLS is a sensitive
measure of cardiac functional impairment in patients with cardiac
involvement, and may detect early cardiac functional improvement
and be an important predictor of cardiac survival.
Details of the presentation are as follows:
|
Title:
Cardiac Response to Chimeric Fibril-Reactive Monoclonal Antibody
11-1F4 in Patientswith AL Amyloidosis with Global Longitudinal
Strain: Results from the Phase 1b trialSession:
Poster Session 1Poster Number: P1-01Date
and Time: Sunday, June 24, 2018, from 9 a.m. to 4
p.m. CDTLocation: Ryman Exhibit Hall, lower level
of the Gaylord Opryland Resort & Convention
CenterPresenter: Sofia Shames, M.D., Columbia
University Medical Center |
The full abstract was published in the June 2018 edition of the
Journal of the American Society of Echocardiography. For more
information on ASE, please visit
http://asescientificsessions.org/.
About Caelum BiosciencesCaelum
Biosciences, Inc. (“Caelum”), a Fortress Biotech (NASDAQ:FBIO)
Company, is a clinical-stage biotechnology company developing
treatments for rare and life-threatening diseases. Caelum’s lead
asset, CAEL-101 (mAb 11-1F4), is a novel antibody for the treatment
of patients with amyloid light chain (“AL”) amyloidosis. Phase
1a/1b data presented at the American Society of Hematology’s 59th
Annual Meeting in December 2017 support CAEL-101’s potential to be
a safe and well-tolerated therapy that promotes amyloid resolution.
CAEL-101 has received Orphan Drug Designation from the U.S. Food
and Drug Administration as a therapeutic agent for patients with AL
amyloidosis, and as a radio-imaging agent in amyloidosis. For more
information, visit www.caelumbio.com.
About Fortress BiotechFortress Biotech, Inc.
(“Fortress”) is a biopharmaceutical company dedicated to acquiring,
developing and commercializing novel pharmaceutical and
biotechnology products. Fortress develops and commercializes
products both within Fortress and through certain subsidiary
companies, also known as Fortress Companies. In addition to its
internal development programs, Fortress leverages its
biopharmaceutical business expertise and drug development
capabilities and provides funding and management services to help
the Fortress Companies achieve their goals. Fortress and the
Fortress Companies may seek licensings, acquisitions, partnerships,
joint ventures and/or public and private financings to accelerate
and provide additional funding to support their research and
development programs. For more information, visit
www.fortressbiotech.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
uncertainties relating to preclinical and clinical testing; risks
relating to the timing of starting and completing clinical trials;
our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such
statement is based, except as required by law.
Contacts:Caelum Biosciences, Inc.Michael
Spector, President & Chief Executive Officer(212)
574-2811mspector@caelumbio.com
Fortress Biotech, Inc.Jaclyn Jaffe, Investor Relations(781)
652-4500ir@fortressbiotech.com
Fortress Biotech, Inc.Laura Bagby, Media Relations6 Degrees(312)
448-8098lbagby@6degreespr.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024